Venus Medtech honored as Outstanding Organization in Adverse Drug Reaction Monitoring and Evaluation in 2020

Recently, the State Adverse Drug Reaction Monitoring Center of the National Medical Products Administration (NMPA) issued the Notice on Commending Outstanding Organizations in Adverse Drug Reaction Monitoring and Evaluation in 2020. As the leader in transcatheter structural heart valvular therapies in China, Venus Medtech (Hangzhou) Inc. (hereinafter "Venus Medtech", 2500.HK) earned the title of Outstanding Pharmaceutical and Medical Device Enterprise in Adverse Drug Reaction Monitoring and Evaluation in 2020.

Adverse event monitoring is critical to the health of patients. This issue has received widespread attention from regulators, pharmaceutical and medical device companies, hospitals, and healthcare professionals. This year, 60 drug and medical device makers were selected as outstanding performers in this regard. Venus Medtech was not only one of the two Zhejiang-based awardees, but also the only medical device company to receive the honor in the province.

As a leading innovative medical device company in the field of structural heart disease in China, Venus Medtech is committed to the health of patients. The company actively reports adverse events to help reduce regulatory burdens. In addition, a clinical data tracking system and real-time logistics monitoring system was created to monitor the use of each implantable product in real-time. Access to the system is open to the NMPA to enable timely and effective supervision. More importantly, the company draws on big data to monitor the safety and efficacy of its products over an extended period, so as to ensure patient safety and continuously improve product quality.

Eric Zi, Founder and General Manager of Venus Medtech, said, "The honor testifies to our efforts to improve the clinical safety of medical devices and our strong sense of social responsibility. As the dominant player in the market with rapid sales growth, it would be negligent for us to underestimate the importance of active safety surveillance." He also pointed out that Venus Medtech would continuously improve its adverse event monitoring system and introduce new monitoring and evaluation techniques, building up capabilities to better promote medical device safety.

Prev:NMPA approves key laboratory jointly established by Venus Medtech

Next:VenusP-Valve obtains special use authorization in UK to enter the market in advance